Fragility clinical trials

Explore recruiting fragility clinical trials.

Recruiting fragility studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fragility trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

THE ALENDRONATE DISCONTINUATION STUDY

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) in patients with Fanconi Anaemia Subtype A: FANCOLEN-I

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Prospective, randomized, multicentre study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and/or worsening of previous vertebral fractures in women with a clinical vertebral fracture or recent hip fracture (imminent risk of fracture) caused by bone fragility.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Basic Toolbox for Lipedema Syndrome Assessment ("BATOLISA")

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Fragility trials by city

Fragility in Toronto Fragility in Vancouver Fragility in Montreal Fragility in Calgary Fragility in Edmonton Fragility in Ottawa Fragility in Winnipeg Fragility in Quebec City Fragility in Hamilton Fragility in Kitchener Fragility in London Fragility in Halifax Fragility in New York Fragility in Los Angeles Fragility in Chicago Fragility in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease